These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 22360399)

  • 1. Current status of immunosuppressive agents for solid organ transplantation in children.
    Coelho T; Tredger M; Dhawan A
    Pediatr Transplant; 2012 Mar; 16(2):106-22. PubMed ID: 22360399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current immunosuppressive agents in pediatric renal transplantation: efficacy, side-effects and utilization.
    Smith JM; Nemeth TL; McDonald RA
    Pediatr Transplant; 2004 Oct; 8(5):445-53. PubMed ID: 15367279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trial of three different immunosuppressive regimens to prevent chronic renal allograft rejection.
    Burke GW; Ciancio C; Blomberg BB; Rosen A; Suzart K; Roth D; Kupin W; Esquenazi V; Miller J
    Transplant Proc; 2002 Aug; 34(5):1610-1. PubMed ID: 12176505
    [No Abstract]   [Full Text] [Related]  

  • 4. Current immunosuppressive agents: efficacy, side effects, and utilization.
    Smith JM; Nemeth TL; McDonald RA
    Pediatr Clin North Am; 2003 Dec; 50(6):1283-300. PubMed ID: 14710781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Balancing efficacy and toxicity in kidney-transplant immunosuppression.
    Leichtman AB
    N Engl J Med; 2007 Dec; 357(25):2625-7. PubMed ID: 18094383
    [No Abstract]   [Full Text] [Related]  

  • 6. Daclizumab as induction therapy in kidney and simultaneous pancreas-kidney transplantation.
    Ciancio G; Mattiazzi A; Miller J; Burke GW
    Minerva Urol Nefrol; 2003 Mar; 55(1):43-56. PubMed ID: 12773966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of immunosuppressive drugs in transplantation.
    Triemer H
    J Med Assoc Ga; 1998 Apr; 87(2):93-6. PubMed ID: 16259250
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen.
    Yang SL; Wang D; Wu WZ; Lin WH; Xu TZ; Cai JQ; Tan JM
    Transpl Immunol; 2008 Jan; 18(3):281-5. PubMed ID: 18047938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New immunodepressant drugs for the prevention and control of kidney transplant rejection].
    Segoloni GP
    G Ital Nefrol; 2005; 22(1):3-15. PubMed ID: 15786373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological surrogates of allograft outcome.
    Mahalati K; Kahan BD
    Ann Transplant; 2000; 5(2):14-23. PubMed ID: 11217202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction antibody therapy in renal transplantation using early steroid withdrawal: long-term results comparing anti-IL2 receptor and anti-thymocyte globulin.
    Libório AB; Mendoza TR; Esmeraldo RM; Oliveira ML; Paes FJ; Silva Junior GB; Daher EF
    Int Immunopharmacol; 2011 Nov; 11(11):1832-6. PubMed ID: 21835269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction therapy for clinical intestinal transplantation: comparison of four different regimens.
    Pinna AD; Weppler D; Nery JR; Khan F; Ruiz P; Kato T; De Faria W; Berho M; Tzakis AG
    Transplant Proc; 2000 Sep; 32(6):1193-4. PubMed ID: 10995902
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacogenetics and immunosuppressive drugs in solid organ transplantation.
    van Gelder T; van Schaik RH; Hesselink DA
    Nat Rev Nephrol; 2014 Dec; 10(12):725-31. PubMed ID: 25247332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daclizumab.
    Mottershead M; Neuberger J
    Expert Opin Biol Ther; 2007 Oct; 7(10):1583-96. PubMed ID: 17916050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can antibody prophylaxis allow sparing of other immunosuppressives?
    Vincenti F; Grinyo J; Ramos E; Nashan B; Stuart F; Kuypers D; Brattstrom C; Cho S; Ekberg H; Johnson R
    Transplant Proc; 1999; 31(1-2):1246-8. PubMed ID: 10083557
    [No Abstract]   [Full Text] [Related]  

  • 16. Three-yr safety and efficacy of everolimus and low-dose cyclosporine in de novo pediatric kidney transplant patients.
    Ferraresso M; Belingheri M; Ginevri F; Murer L; Dello Strologo L; Cardillo M; Parodi A; Ghirardo G; Guzzo I; Innocente A; Ghio L
    Pediatr Transplant; 2014 Jun; 18(4):350-6. PubMed ID: 24802342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Everolimus in combination with cyclosporin a as pre- and posttransplantation immunosuppressive therapy in nonmyeloablative allogeneic hematopoietic stem cell transplantation.
    Junghanss C; Rathsack S; Wacke R; Weirich V; Vogel H; Drewelow B; Mueller S; Altmann S; Freund M; Lange S
    Biol Blood Marrow Transplant; 2012 Jul; 18(7):1061-8. PubMed ID: 22182476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zenapax versus OKT-3 prophylaxis in immunologically high-risk kidney transplant recipients.
    Lácha J; Símová M; Nosková L; Teplan V; Vítko S
    Transplant Proc; 2001 May; 33(3):2273-4. PubMed ID: 11377526
    [No Abstract]   [Full Text] [Related]  

  • 19. Overview of transplantation immunology and the pharmacotherapy of adult solid organ transplant recipients: focus on immunosuppression.
    Bush WW
    AACN Clin Issues; 1999 May; 10(2):253-69; quiz 304-6. PubMed ID: 10578712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction therapy: why, when, and which agent?
    Krischock L; Marks SD
    Pediatr Transplant; 2010 May; 14(3):298-313. PubMed ID: 20345609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.